The average survival time of GBM patients is about 15 months and the 5-year survival rate is less than 5%.7–11 In clinic, majority of GBM patients (about 90%) are diagnosed with wild-type IDH1/2 and have no glioma history, which is defined as primary or de novo GBM. Here, IDH1 is linked to central nervous system cancer.